Exondys 51 is owned by Sarepta Theraps Inc.

Exondys 51 contains Eteplirsen.

Exondys 51 has a total of 12 drug patents out of which 2 drug patents have expired.

Expired drug patents of Exondys 51 are:

• US10533174
• US9416361

Exondys 51 was authorised for market use on 19 September, 2016.

Exondys 51 is available in solution;intravenous dosage forms.

Exondys 51 can be used as treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping, treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by inducing skipping of exon 51, restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping, treatment of dmd in patients having a mutation of the dmd gene that is amenable to exon 51 skipping, (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; or (iii) inducing skipping; each of (i)-(iii) in patients having a confirmed mutation of the dmd gene that is amenable to exon 51 skipping, increasing production of functional dystrophin protein in dmd patients having a mutation of the dmd gene that is amenable to exon 51 skipping.

Drug patent challenges can be filed against Exondys 51 from 19 September, 2020.

The generics of Exondys 51 are possible to be released after 14 March, 2034.